Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This is the early access programme (EAP) of sorafenib in the indication of advanced renal
cell carcinoma (RCC). The study is to evaluate the efficacy and safety of sorafenib in
patients with advanced RCC.